Compare TotalEnergies SE (TTE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs Vertex Pharmaceuticals Incorporated — how do they compare? TotalEnergies SE trades at $80.89 (market cap $179.99B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: TotalEnergies SE is the larger of the two by market cap, and TotalEnergies SE pays a 5.22% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TTE | VRTX | |
|---|---|---|
Market Cap | $179.99B | $121.95B |
Sector | Energy | Health |
52-Week High | $93.60 | $529.59 |
52-Week Low | $57.39 | $366.54 |
Enterprise Value | $214.14B | $116.69B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
